Laboratory of Precision and Nanomedicine develops smart cancer therapeutics with increased potency and decreased side effects.
Our mission is to change the perception of cancer as being a largely incurable disease. We use in vivo peptide phage display screens to identify homing peptides that bind to specific targets in the vasculature. Corresponding synthetic peptides are explored for targeting drugs, biologicals, and nanoparticles into tumors to increase their therapeutic index. We focus on development of novel diagnostic tests and therapeutics for the early detection and precision treatment of solid tumors (glioblastoma, and breast, prostate ovarian, prostate, and colorectal carcinoma). Our lab is also at the forefront of development of next generation peptidic shuttles capable of efficient and high capacity payload delivery across the blood brain barrier.
Internationally recognized nanomedicine expert Prof. Hélder A. Santos becomes Visiting Professor at our laboratory
Written on Thursday, 04 February 2021 11:14With the global benefits of the new science of nanomedicine growing each year, the University of Tartu is determined to stay at the forefront of…
New tools to increase the reliability of in vivo phage biopanning reported in Nucleic Acids Research
Written on Thursday, 04 February 2021 09:46In vivo phage display is widely used for the identification of organ- or disease-specific homing peptides. In our study (lead authors PhD students Karlis Pleiko…
Congratulations to Prakash Lingasamy for successfully defending his PhD thesis!
Written on Monday, 01 February 2021 11:08Prakash Lingasamy successfully defended his Ph.D. thesis " Development of multitargeted tumor penetrating peptides" on January 29th, 2021. Opponent of the thesis was professor Angelo…
In vivo phage display: identification of organ-specific peptides using deep sequencing and differential profiling across tissues
Written on Thursday, 04 February 2021 10:34Pleiko K, Põšnograjeva K, Haugas M, Paiste P, Tobi A, Kurm K, Riekstina U, Teesalu T. Nucleic Acids Res. 2021 Jan 14, Online ahead of print.…Read more...
Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity
Written on Wednesday, 16 December 2020 11:38Ludovico Cantuti-Castelvetri, Ravi Ojha, Liliana D Pedro, Minou Djannatian, Jonas Franz, Suvi Kuivanen, Franziska van der Meer, Katri Kallio, Tuğberk Kaya, Maria Anastasina, Teemu Smura,…Read more...
OctoberPeptide targeted polymersomes bind to M2 human macrophagesPolymersomes targeted with an M2 macrophage binding peptide (green) identified in our lab using phage display bind to and are taken up by M2s (red) originated from human primary monocytes.…
SeptemberPolymersomes targeted with an M2 macrophage binding peptide in a mouse model of triple negative breast cancerPolymersomes targeted with an M2 macrophage binding peptide (green) identified in our lab using phage display home to M2 TAMs (red) after intravenous administration in a mouse model of triple…
JanuaryHigh infiltration of CD206+ cells in human breast tumorsImmunohistochemical staining of human CD206 (brown) with nuclear counterstain (Hematoxilin, in dark blue). Authors: Anni Lepland and Pablo Scodeller.